Investor Outlook: Indivior Plc (LON:INDV) “Buy” Rating Reconfirmed by Numis Today

June 19, 2018 - By Adrian Erickson

Indivior PLC (LON:INDV) Logo

Indivior Plc (LON:INDV) Rating Reaffirmed

This Morning, Tuesday morning, Indivior Plc (LON:INDV)‘s “Buy” rating was restate by Numis in an analyst report.

Indivior PLC (LON:INDV) Ratings Coverage

Among 5 analysts covering Indivior Plc (LON:INDV), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Indivior Plc has GBX 640 highest and GBX 398 lowest target. GBX 523.60’s average target is 44.56% above currents GBX 362.2 stock price. Indivior Plc had 17 analyst reports since January 17, 2018 according to SRatingsIntel. The stock has “Buy” rating by Numis Securities on Wednesday, May 2. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, March 23. The firm has “Buy” rating given on Tuesday, May 8 by Jefferies. The rating was maintained by Jefferies with “Buy” on Monday, April 9. The company was maintained on Friday, June 15 by RBC Capital Markets. Jefferies maintained Indivior PLC (LON:INDV) on Friday, June 15 with “Buy” rating. Numis Securities maintained the stock with “Buy” rating in Friday, June 15 report. The stock of Indivior PLC (LON:INDV) earned “Buy” rating by Jefferies on Wednesday, January 17. The rating was maintained by Morgan Stanley with “Equal Weight” on Tuesday, April 3. The company was maintained on Friday, January 26 by RBC Capital Markets.

The stock decreased 1.12% or GBX 4.1 during the last trading session, reaching GBX 362.2. About 1.89 million shares traded. Indivior PLC (LON:INDV) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence worldwide. The company has market cap of 2.64 billion GBP. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It has a 40.24 P/E ratio. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

More news for Indivior PLC (LON:INDV) were recently published by:, which released: “Indivior’s Mark Crossley to Participate in Jefferies 2018 Global Healthcare Conference on June 5th” on May 24, 2018.‘s article titled: “Indivior Is Granted Temporary Restraining Order” and published on June 16, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.